1. Home
  2. CHEK vs XRTX Comparison

CHEK vs XRTX Comparison

Compare CHEK & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHEK
  • XRTX
  • Stock Information
  • Founded
  • CHEK 2004
  • XRTX 2011
  • Country
  • CHEK Israel
  • XRTX Canada
  • Employees
  • CHEK N/A
  • XRTX N/A
  • Industry
  • CHEK Medical Electronics
  • XRTX Pharmaceuticals and Biotechnology
  • Sector
  • CHEK Health Care
  • XRTX Health Care
  • Exchange
  • CHEK Nasdaq
  • XRTX Nasdaq
  • Market Cap
  • CHEK 5.1M
  • XRTX 4.1M
  • IPO Year
  • CHEK 2015
  • XRTX N/A
  • Fundamental
  • Price
  • CHEK $0.61
  • XRTX $1.15
  • Analyst Decision
  • CHEK
  • XRTX Strong Buy
  • Analyst Count
  • CHEK 0
  • XRTX 1
  • Target Price
  • CHEK N/A
  • XRTX $14.00
  • AVG Volume (30 Days)
  • CHEK 14.0K
  • XRTX 16.7K
  • Earning Date
  • CHEK 02-14-2025
  • XRTX 11-15-2024
  • Dividend Yield
  • CHEK N/A
  • XRTX N/A
  • EPS Growth
  • CHEK N/A
  • XRTX N/A
  • EPS
  • CHEK N/A
  • XRTX N/A
  • Revenue
  • CHEK N/A
  • XRTX N/A
  • Revenue This Year
  • CHEK N/A
  • XRTX N/A
  • Revenue Next Year
  • CHEK N/A
  • XRTX N/A
  • P/E Ratio
  • CHEK N/A
  • XRTX N/A
  • Revenue Growth
  • CHEK N/A
  • XRTX N/A
  • 52 Week Low
  • CHEK $0.61
  • XRTX $1.09
  • 52 Week High
  • CHEK $3.45
  • XRTX $7.00
  • Technical
  • Relative Strength Index (RSI)
  • CHEK 19.90
  • XRTX 40.84
  • Support Level
  • CHEK $0.61
  • XRTX $1.14
  • Resistance Level
  • CHEK $0.63
  • XRTX $1.25
  • Average True Range (ATR)
  • CHEK 0.04
  • XRTX 0.09
  • MACD
  • CHEK -0.00
  • XRTX 0.01
  • Stochastic Oscillator
  • CHEK 0.00
  • XRTX 10.71

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: